Hong Kong Chief Executive John Lee delivered the 2025 Policy Address to the Legislative Council this morning (Sept. 17). He pointed out that the government will attract more top-notch international and mainland pharmaceutical companies to set up operations in HK and will also expedite the "1+" mechanism for new drugs.
Lee said that attracting more pharmaceutical companies to set up operations in HK will help to conduct clinical trials and medical treatments for rare disease drugs, high-end cancer drugs, and advanced therapy products. The establishment of the International Clinical Trial Academy for nurturing clinical trial professionals in the GBA, as well as international summits and forums, is also under preparation.
In addition, he also stressed that the government will expedite the "1+" mechanism for new drugs, piloting priority evaluation and approval of innovative drugs recommended by the Hospital Authority for treatment of severe or rare diseases. "This will help pharmaceutical companies bring innovative drugs to the market sooner," he said.
Related News:
Comment